CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
cilengitide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00679354
NCT00679354Phase 2Completed

Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma

National Cancer Institute (NCI)·interventional·Posted May 16, 2008·Updated Aug 1, 2018

In Brief

A Phase 2 clinical trial evaluating cilengitide, laboratory biomarker analysis, and 1 other intervention for Childhood High-grade Cerebellar Astrocytoma and 9 related conditions. Completed, enrolled 30 participants across 20 sites in 2 countries.

Detailed Summary

This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.

Study Details

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 16, 2008
Enrollment StartJun 1, 2008
Primary CompletionOct 1, 2010
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.1 years ago

Interventions

cilengitidedrug

Given IV

laboratory biomarker analysisother

Correlative studies

pharmacological studyother

Correlative studies